New and emerging biomarkers in cardiovascular disease

Area of Science:

• Biochemistry
• Cardiology
• Metabolomics

Background:

• Cardiovascular disease (CVD) remains a leading global cause of mortality and morbidity.
• Identifying novel risk factors and metabolic pathways is crucial for effective CVD prevention and management.
• Current research aims to improve individual risk stratification and develop new therapeutic strategies.

Purpose of the Study:

• To review emerging biomarkers associated with CVD risk.
• To explore the role of lipid metabolism, glycemia, inflammation, and cardiac damage in CVD pathophysiology.
• To assess the potential clinical utility and therapeutic implications of these novel biomarkers.

Main Methods:

• Literature review of recent studies on CVD biomarkers.
• Analysis of biomarkers related to lipid metabolism, glucose regulation, inflammatory processes, and myocardial injury.
• Evaluation of the potential for risk stratification and therapeutic targeting.

Main Results:

• Several novel biomarkers show promising associations with CVD risk.
• These biomarkers offer insights into the underlying pathophysiology of cardiovascular disease.
• Emerging markers related to lipid metabolism, glycemia, inflammation, and cardiac damage are highlighted.

Conclusions:

• Novel biomarkers in lipid metabolism, glycemia, inflammation, and cardiac damage show potential for CVD risk assessment.
• Standardization of measurement methodologies and further validation in diverse populations are required.
• These biomarkers represent promising targets for future CVD therapies and interventions.